Walk into any dermatology clinic in Gangnam and you'll hear the same three letters: PDRN. Polydeoxyribonucleotide — a DNA fragment extracted from salmon — has moved from injectable "rejuran" treatments into topical skincare at remarkable speed, and in 2026 it is the single most requested ingredient by overseas buyers on RawPick.
The science is catching up with the hype. Korean suppliers have scaled fermentation-free extraction to pharmaceutical purity above 98%, driving raw material costs down nearly 40% in eighteen months. That price curve is what turned PDRN from a clinic-only actives into a mass-market serum ingredient.
Not all PDRN is equal. The three fields that matter on a Korean CoA: molecular weight distribution (50–1,500 kDa is the sweet spot for topical absorption), sodium content consistency, and endotoxin levels. Suppliers listed on RawPick provide all three, verified.
Regulatory posture also differs by market. Japan treats topical PDRN as a cosmetic ingredient with concentration guidance; China requires new-ingredient registration unless you formulate below the 2024 threshold. Vietnam currently follows ASEAN cosmetic directive defaults.
